Overview

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Status:
Active, not recruiting
Trial end date:
2022-09-26
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week open-label extension period.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation